Skip to main content

Table 4 Clinical Events after Treatment for In-stent Restenosis at 5 years

From: Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions

Variables

Overall population

Matched population

PCB (n = 32)

Non-PCB (n = 74)

p

PCB (n = 25)

Non-PCB (n = 25)

p

Recurrent ISR at 5 years

8 (25.0)

53 (71.6)

< 0.001

6 (24.0)

20 (80.0)

< 0.001

All-cause death at 5 years

4 (12.5)

9 (12.2)

0.963

4 (16.0)

3 (12.0)

0.699

Target lesion revascularization at 5 years

5 (15.6)

30 (40.5)

0.006

4 (16.0)

11 (44.0)

0.020

Unplanned major amputation at 5 years

0 (0.0)

1 (1.4)

0.491

0 (0.0)

0 (0.0)

1.000

  1. Categorical variables are expressed as number and percentage, and are calculated based on Kaplan-Meier estimate
  2. ISR indicates in-stent restenosis, PCB paclitaxel-coated balloon